We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

87 hedge funds and large institutions have $637M invested in Adaptimmune Therapeutics in 2020 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more call options, than puts

Call options by funds: $1.23M | Put options by funds: $767K

42% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 19

42% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 19

10% more funds holding

Funds holding: 79 → 87 (+8)

1.26% less ownership

Funds ownership: 13.99% → 12.74% (-1.3%)

38% less capital invested

Capital invested by funds: $1.03B → $637M (-$393M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
87
Holders Change
+8
Holders Change %
+10.13%
% of All Funds
1.54%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
27
Increased
27
Reduced
19
Closed
19
Calls
$1.23M
Puts
$767K
Net Calls
+$463K
Net Calls Change
-$522K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$27.7M
2
BBA
Baker Bros. Advisors
New York
+$19M
3
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$17.8M
4
PHS
PFM Health Sciences
California
+$10M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$9.51M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$48M
2
ACA
Avoro Capital Advisors
New York
-$40.5M
3
Victory Capital Management
Victory Capital Management
Texas
-$23.3M
4
RI
RTW Investments
New York
-$20.9M
5
FCM
Farallon Capital Management
California
-$20.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Acadian Asset Management
26
Acadian Asset Management
Massachusetts
$1.63M +$1.64M +301,408 New
AA
27
ALPS Advisors
Colorado
$1.51M +$448K +82,380 +42%
California Public Employees Retirement System
28
California Public Employees Retirement System
California
$1.48M -$28.8K -5,300 -2%
UBS Group
29
UBS Group
Switzerland
$978K +$306K +56,249 +45%
SFI
30
Susquehanna Fundamental Investments
Pennsylvania
$926K +$372K +68,415 +66%
HS
31
HighVista Strategies
Massachusetts
$859K +$564K +103,872 +187%
Rafferty Asset Management
32
Rafferty Asset Management
New York
$803K +$810K +149,060 New
Susquehanna International Group
33
Susquehanna International Group
Pennsylvania
$796K +$803K +147,801 New
WM
34
WS Management
Florida
$655K – – –
Man Group
35
Man Group
United Kingdom
$558K +$162K +29,819 +40%
AC
36
Athanor Capital
New York
$524K +$187K +34,492 +55%
ECM
37
ExodusPoint Capital Management
New York
$415K +$252K +46,313 +151%
VEA
38
Virtus ETF Advisers
New York
$388K +$222K +40,945 +132%
Vontobel Holding
39
Vontobel Holding
Switzerland
$377K +$380K +70,000 New
Squarepoint
40
Squarepoint
New York
$300K -$41.2K -7,585 -12%
Goldman Sachs
41
Goldman Sachs
New York
$275K -$2.91M -535,395 -91%
Mitsubishi UFJ Asset Management
42
Mitsubishi UFJ Asset Management
Japan
$274K +$277K +50,907 New
Northern Trust
43
Northern Trust
Illinois
$270K +$272K +50,000 New
Geode Capital Management
44
Geode Capital Management
Massachusetts
$265K -$334K -61,467 -56%
Citigroup
45
Citigroup
New York
$261K +$258K +47,441 +4,467%
State of Tennessee, Department of Treasury
46
State of Tennessee, Department of Treasury
Tennessee
$255K +$257K +47,240 New
AA
47
AlphaCentric Advisors
Puerto Rico
$237K +$216K +39,800 +948%
KBC Group
48
KBC Group
Belgium
$231K – – –
BIM
49
Bogle Investment Management
Massachusetts
$229K +$231K +42,515 New
JF
50
Jump Financial
Illinois
$215K +$216K +39,800 New
1
2
3 4 5

ADAP Hedge Fund Activity: Q4 2020 in Review

87 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2020, worth a combined $637M — down 38% from $1.03B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new ADAP positions and 19 closed out — a net gain of 8 holders — while 27 added to existing stakes and 19 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $27.7M. The largest seller was RA Capital Management, cutting an estimated $48M.

  • 87 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2020, up from 79 in Q3 2020.
  • Funds reported $637M of Adaptimmune Therapeutics stock for Q4 2020, down 38% quarter-over-quarter.
  • 27 funds opened new Adaptimmune Therapeutics positions in Q4 2020 and 19 closed out, a net change of +8 holders.
  • The largest Adaptimmune Therapeutics buyer in Q4 2020 was Morgan Stanley, an estimated $27.7M added.
  • The largest Adaptimmune Therapeutics seller in Q4 2020 was RA Capital Management, an estimated $48M sold.

Based on aggregated 13F filings for Q4 2020.